S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
Stocks drift as strong week for Wall Street heads for close
NASDAQ:ELYM

Eliem Therapeutics - ELYM Stock Forecast, Price & News

$3.85
0.00 (0.00%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.85
▼
$3.85
50-Day Range
$2.48
▼
$4.64
52-Week Range
$2.36
▼
$11.51
Volume
190 shs
Average Volume
16,242 shs
Market Capitalization
$102.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Eliem Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
55.8% Upside
$6.00 Price Target
Short Interest
Healthy
0.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.03mentions of Eliem Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.88) to ($1.60) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

669th out of 1,055 stocks

Pharmaceutical Preparations Industry

339th out of 519 stocks

See Top Rated MarketRank™ Stocks Here

ELYM stock logo

About Eliem Therapeutics (NASDAQ:ELYM) Stock

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.

Receive ELYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ELYM Stock News Headlines

November 30, 2022 | finance.yahoo.com
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
November 14, 2022 | finanznachrichten.de
Eliem Therapeutics, Inc.: Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
January 28, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
November 12, 2022 | finance.yahoo.com
Is Eliem Therapeutics (NASDAQ:ELYM) In A Good Position To Invest In Growth?
November 8, 2022 | finance.yahoo.com
Eliem Therapeutics to Participate at Two Upcoming Investor Conferences
August 18, 2022 | seekingalpha.com
Eliem Therapeutics (ELYM) Investor Presentation - Slideshow
August 15, 2022 | msn.com
Eliem Therapeutics: Q2 Earnings Insights
August 15, 2022 | finance.yahoo.com
Eliem Therapeutics Reports Second Quarter Financial and Business Highlights
January 28, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
August 2, 2022 | nasdaq.com
Eliem Therapeutics Discontinues ETX-810 Program As Phase 2a Trial In Sciatica Fails
August 2, 2022 | finance.yahoo.com
Eliem Therapeutics Shares Fall On Lower Back Pain Trial Setback
August 2, 2022 | finance.yahoo.com
Eliem's stock slides 20% after saying it will discontinue development of pain treatment
August 2, 2022 | marketwatch.com
Eliem Therapeutics Scraps Lead Candidate After Study Failure >ELYM
August 2, 2022 | finance.yahoo.com
Eliem Therapeutics Provides ETX-810 Program Update
July 11, 2022 | markets.businessinsider.com
SVB Leerink Maintains Outperform Rating for Eliem Therapeutics: Here's What You Need To Know
July 7, 2022 | finance.yahoo.com
Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022
June 27, 2022 | finance.yahoo.com
Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)
May 17, 2022 | seekingalpha.com
Harpoon Therapeutics, Grove top healthcare gainers; Chimerix, Eliem lead losers' pack
May 16, 2022 | finance.yahoo.com
Eliem Therapeutics Reports First Quarter Financial and Business Highlights
May 9, 2022 | finance.yahoo.com
Eliem Therapeutics, Inc. (ELYM) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
April 28, 2022 | benzinga.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Eliem Therapeutics, Inc. - ELYM
April 26, 2022 | benzinga.com
Guggenheim Downgrades Eliem Therapeutics to Neutral
April 25, 2022 | markets.businessinsider.com
Mid-Afternoon Market Update: Nasdaq Rises 70 Points; Eliem Therapeutics Shares Slide
April 25, 2022 | seekingalpha.com
Eliem stock tanks 54% as ETX-810 fails in diabetic pain study; delays enrollment in depression trial of ETX-155
April 25, 2022 | marketwatch.com
Eliem Therapeutics Shares Plummet After Double Pipeline Setbacks >ELYM
April 25, 2022 | finance.yahoo.com
Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs
April 25, 2022 | marketwatch.com
Eliem Therapeutics Reports Setback in ETX-810, ETX-155 >ELYM
See More Headlines
Receive ELYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ELYM Company Calendar

Last Earnings
11/14/2022
Today
1/28/2023
Next Earnings (Estimated)
3/06/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ELYM
CUSIP
N/A
CIK
1768446
Web
www.eliemtx.com
Phone
425-276-2300
Fax
N/A
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+55.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-47,480,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-31.38%
Return on Assets
-29.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
21.21
Quick Ratio
21.21

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.30 per share
Price / Book
0.61

Miscellaneous

Outstanding Shares
26,570,000
Free Float
25,319,000
Market Cap
$102.29 million
Optionable
Not Optionable
Beta
0.56

Key Executives

  • Mr. Robert W. Azelby M.B.A. (Age 54)
    Pres, CEO & Director
    Comp: $941.6k
  • Ms. Erin M. Lavelle (Age 45)
    Exec. VP, COO & CFO
    Comp: $681.79k
  • Dr. Valerie Morisset Ph.D. (Age 52)
    Chief Scientific Officer and Exec. VP of R&D
    Comp: $557.32k
  • Mr. James B. Bucher J.D. (Age 56)
    Exec. VP, Gen. Counsel & Sec.
  • Ms. Jo Palmer-Phillips Ph.D.
    Chief Devel. Officer
  • Dr. Mark Versavel M.B.A. (Age 63)
    M.D., MBA, Ph.D., Interim Chief Medical Officer
  • Ms. Susan Franks M.S.
    Sr. VP & Head of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













ELYM Stock - Frequently Asked Questions

Should I buy or sell Eliem Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eliem Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ELYM shares.
View ELYM analyst ratings or view top-rated stocks.

What is Eliem Therapeutics' stock price forecast for 2023?

3 equities research analysts have issued 1-year price objectives for Eliem Therapeutics' stock. Their ELYM share price forecasts range from $4.00 to $8.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 55.8% from the stock's current price.
View analysts price targets for ELYM or view top-rated stocks among Wall Street analysts.

How have ELYM shares performed in 2023?

Eliem Therapeutics' stock was trading at $3.67 on January 1st, 2023. Since then, ELYM shares have increased by 4.9% and is now trading at $3.85.
View the best growth stocks for 2023 here.

Are investors shorting Eliem Therapeutics?

Eliem Therapeutics saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 21,000 shares, an increase of 81.0% from the December 31st total of 11,600 shares. Based on an average daily volume of 7,000 shares, the short-interest ratio is presently 3.0 days. Approximately 0.1% of the company's shares are sold short.
View Eliem Therapeutics' Short Interest.

When is Eliem Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our ELYM earnings forecast.

How were Eliem Therapeutics' earnings last quarter?

Eliem Therapeutics, Inc. (NASDAQ:ELYM) released its quarterly earnings results on Monday, November, 14th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.05.

When did Eliem Therapeutics IPO?

(ELYM) raised $75 million in an initial public offering on Tuesday, August 10th 2021. The company issued 6,000,000 shares at $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

What is Eliem Therapeutics' stock symbol?

Eliem Therapeutics trades on the NASDAQ under the ticker symbol "ELYM."

How do I buy shares of Eliem Therapeutics?

Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eliem Therapeutics' stock price today?

One share of ELYM stock can currently be purchased for approximately $3.85.

How much money does Eliem Therapeutics make?

Eliem Therapeutics (NASDAQ:ELYM) has a market capitalization of $102.29 million. The company earns $-47,480,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis.

How can I contact Eliem Therapeutics?

The official website for the company is www.eliemtx.com. The company can be reached via phone at 425-276-2300 or via email at investorrelations@eliemtx.com.

This page (NASDAQ:ELYM) was last updated on 1/28/2023 by MarketBeat.com Staff